AK
Aktis Oncology, Inc.
AKTS · NASDAQ
$21.88 -4.29% (-$0.98)
1M -8.63%
Market Cap $1.22B
P/E Ratio -
Div. Yield -
ROE 35.78%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 187.91x
EV/EBITDA N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 980.93%
Op. margin 1,149.52%
FCF margin 1,134.54%
Quality
0 /100
Poor ROE 35.78%
ROA 24.06%
Asset turnover 0.02x
Debt
100 /100
Low Current ratio 7.37x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
47 /100
Moderate EPS volatility 36.42%
Profitable years 0
Beta 0.45x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o AKTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Roden
Employees
79
Headquarters
Boston
Nadchodzące wydarzenia
12 LIS
Earnings
Upcoming earnings report